Wechselwirkungen von Veresterte Estrogene und Methyltestosteron

Primary forms of contraception include: tubal ligation, partner’s vasectomy, intrauterine devices, birth control pills, and injectable/implantable/insertable/topical hormonal birth control products. (Fachinformation zu Acitretin, Boxed Warning (umrahmter Warnhinweis))

Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (Fachinformation zu Anastrozol, Arzneimittelwechselwirkungen)

CONTRAINDICATIONS: Precocious puberty, prostatic carcinoma or other androgen-dependent neoplasm, prior allergic reaction to HCG. (Fachinformation zu Choriongonadotropin, Gegenanzeigen)

(See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

These drugs include, but are not limited to, the following: the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin the androgen receptor inhibitor enzalutamide the antimycobacterials rifampin, rifapentine the cytotoxic agent mitotane St. (Fachinformation zu Doravirin, Gegenanzeigen)

(See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

(See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

(See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

(See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

(See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

(See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (Fachinformation zu Exemestan, Warnhinweise und Vorsichtsmaßnahmen)

Because of the ability of Type II 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (DHT), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant female who receives finasteride. (Fachinformation zu Finasterid, Gegenanzeigen)

(See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

Women taking estrogen-containing oral contraceptives may be at increased risk of becoming pregnant while on griseofulvin (see also PRECAUTIONS, Drug Interactions ) . (Fachinformation zu Griseofulvin, Gegenanzeigen)

Johanniskraut kann die Wirksamkeit der Antibabypille verringern. (NCCIH, St. John's Wort)

…Women's Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

…Women's Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

(See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

(See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

…Women's Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

(See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

(See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

Sensitive CYP3A substrates including hormonal contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index. (Fachinformation zu Mitapivat, Arzneimittelwechselwirkungen)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (Fachinformation zu Mitotan, Arzneimittelwechselwirkungen)

(See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

(See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

(See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

(See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

(See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

(See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Boxed Warning (umrahmter Warnhinweis))

Concomitant Use with Systemic Estrogens : Not recommended. (Fachinformation zu Raloxifen, Warnhinweise und Vorsichtsmaßnahmen)

Moderate or Weak CYP1A2 Inhibitors Concomitant use of Zanaflex with moderate or weak CYP1A2 inhibitors (e.g., zileuton, antiarrhythmics [amiodarone, mexiletine, propafenone, and verapamil], cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided. (Fachinformation zu Tizanidin, Arzneimittelwechselwirkungen)

Concomitant use of combined hormonal contraceptives ( 4.1 ) (Fachinformation zu Tranexamsäure, Gegenanzeigen)

John's Wort (CYP450 inducer; P-gp inducer) Significantly Reduced Contraindicated Oral Contraceptives containing ethinyl estradiol and norethindrone (CYP2C19 Inhibition) Increased Monitoring for adverse reactions and toxicity related to voriconazole is recommended for concomitant administration with oral contraceptives. (Fachinformation zu Voriconazol, Arzneimittelwechselwirkungen)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (Fachinformation zu Alogliptin und Metformin, Arzneimittelwechselwirkungen)

Estrogen Estrogen containing oral contraceptives decrease theophylline clearance in a dose-dependent fashion. (Fachinformation zu Aminophyllin, Arzneimittelwechselwirkungen)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Fachinformation zu Amlodipin und Atorvastatin, Arzneimittelwechselwirkungen)

Amoxicillin may reduce the efficacy of oral contraceptives. (Fachinformation zu Amoxicillin, Arzneimittelwechselwirkungen)

Amoxicillin and Clavulanate Potassium Extended Release Tablets may reduce efficacy of oral contraceptives. (Fachinformation zu Amoxicillin und Clavulansäure, Arzneimittelwechselwirkungen)

Oral Contraceptives : May be less effective and increased breakthrough bleeding may occur. (Fachinformation zu Ampicillin, Arzneimittelwechselwirkungen)

Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

Hormonal Contraceptives : Efficacy of contraceptives may be reduced during and for 28 days following administration of aprepitant. (Fachinformation zu Aprepitant, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

Hormonal contraceptives: ethinyl estradiol and norgestimate or norethindrone ↓ ethinyl estradiol ↑ norgestimate c ↑ ethinyl estradiol ↑ norethindrone d Use caution if considering coadministration of oral contraceptives with REYATAZ or REYATAZ with ritonavir. (Fachinformation zu Atazanavir, Arzneimittelwechselwirkungen)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.3 ). (Fachinformation zu Atorvastatin, Arzneimittelwechselwirkungen)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Fachinformation zu Bismutsubcitrat, Metronidazol und Tetracyclin, Arzneimittelwechselwirkungen)

Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

Hormonal contraceptives: TRACLEER use decreases contraceptive exposure and reduces effectiveness ( 7.2 ). (Fachinformation zu Bosentan, Arzneimittelwechselwirkungen)

Drugs without Clinically Significant Interactions with Cabotegravir Based on drug interaction study results, the following drugs can be coadministered with cabotegravir without a dose adjustment: etravirine, midazolam, oral contraceptives containing levonorgestrel and ethinyl estradiol, rifabutin, and rilpivirine [see Clinical Pharmacology ( 12.3 )] . (Fachinformation zu Cabotegravir, Arzneimittelwechselwirkungen)

Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (Fachinformation zu Calciumchlorid, Arzneimittelwechselwirkungen)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (Fachinformation zu Carbamazepin, Warnhinweise und Vorsichtsmaßnahmen)

Oral Contraceptives: Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. (Fachinformation zu Cenobamat, Arzneimittelwechselwirkungen)

Oral Contraceptives (Estrogen, Progestin) In 7 healthy females who were using single-ingredient progestin or combination estrogen-containing oral contraceptives, the pharmacokinetic parameters of a single 600 mg dose of quinine sulfate were not altered in comparison to those observed in 7 age-matched female control subjects not using oral contraceptives. (Fachinformation zu Chinin, Arzneimittelwechselwirkungen)

Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)

…itraconazole clarithromycin Amiodarone verapamil ketoconazole erythromycin Bromocriptine voriconazole quinupristin/ dalfopristin colchicine danazol imatinib metoclopramide nefazodone oral contraceptives HIV Protease Inhibitors The HIV protease inhibitors (e.g., indinavir, nelfinavir, ritonavir, and saquinavir) are known to inhibit cytochrome P-450 3A and thus could… (Fachinformation zu Ciclosporin, Arzneimittelwechselwirkungen)

Concomitant use with colesevelam hydrochloride may decrease the exposure of the following drugs: Drugs with a narrow therapeutic index (e.g., cyclosporine), phenytoin, thyroid hormone replacement therapy, warfarin, oral contraceptives containing ethinyl estradiol and norethindrone, olmesartan medoxomil, and sulfonylureas (glimepiride, glipizide, glyburide). (Fachinformation zu Colesevelam, Arzneimittelwechselwirkungen)

Drug Interactions Cholestyramine for Oral Suspension USP may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. (Fachinformation zu Colestyramin, Arzneimittelwechselwirkungen)

Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

Hormonal contraceptives : Effective alternative (non-hormonal) contraceptive method or a barrier method of contraception is recommended [see Use in Specific Populations (8.3) ] . ethinyl estradiol, norethindrone, drospirenone ↓ ethinyl estradiol ↓ norethindrone drospirenone: effects unknown For co-administration with drospirenone, clinical monitoring is recommended… (Fachinformation zu Darunavir, Arzneimittelwechselwirkungen)

Hormonal contraceptives: Additional or alternative (non-hormonal) forms of contraception should be considered when estrogen-containing contraceptives are co-administered with PREZCOBIX or PREZCOBIX PED [see Use in Specific Populations (8.3) ] . drospirenone/ethinylestradiol ↑ drospirenone ↓ ethinylestradiol For co-administration with drospirenone, clinical monitoring… (Fachinformation zu Darunavir und Cobicistat, Arzneimittelwechselwirkungen)

…budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil,… (Fachinformation zu Deferasirox, Arzneimittelwechselwirkungen)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (Fachinformation zu Deutetrabenazin, Warnhinweise und Vorsichtsmaßnahmen)

(‎ 7.1 ) • Concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thromboembolism. (Fachinformation zu Dexamethason, Arzneimittelwechselwirkungen)

…following drugs can be coadministered with dolutegravir without a dose adjustment: atazanavir/ritonavir, darunavir/ritonavir, elbasvir/grazoprevir, methadone, midazolam, omeprazole, oral contraceptives containing norgestimate and ethinyl estradiol, prednisone, rifabutin, rilpivirine, sofosbuvir/velpatasvir, and tenofovir [see Clinical Pharmacology ( 12.3 )] . (Fachinformation zu Dolutegravir, Arzneimittelwechselwirkungen)

Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Fachinformation zu Elexacaftor, Tezacaftor und Ivacaftor, Arzneimittelwechselwirkungen)

Hormonal Contraceptives: drospirenone/ethinyl estradiol levonorgestrel norgestimate/ethinyl estradiol ↑ drospirenone ↑ norgestimate ↑ levonorgestrel ↓ ethinyl estradiol Additional or alternative non-hormonal forms of contraception should be considered when estrogen based contraceptives are coadministered with GENVOYA. (Fachinformation zu Elvitegravir, Cobicistat, Emtricitabin und Tenofovir, Arzneimittelwechselwirkungen)

Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (Fachinformation zu Eslicarbazepin, Arzneimittelwechselwirkungen)

Effects of Felbatol ® on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 µg ethinyl estradiol and 75 µg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive… (Fachinformation zu Felbamat, Arzneimittelwechselwirkungen)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (Fachinformation zu Flibanserin, Arzneimittelwechselwirkungen)

Oral contraceptives Two pharmacokinetic studies with a combined oral contraceptive have been performed using multiple doses of fluconazole. (Fachinformation zu Fluconazol, Arzneimittelwechselwirkungen)

Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds)—enhanced tendency toward edema. (Fachinformation zu Fludrocortison, Arzneimittelwechselwirkungen)

Use of ultrasound monitoring of ovarian response and/or measurement of serum estradiol levels is important to minimize the risk of overstimulation [see Warnings and Precautions (5.8) ] . (Fachinformation zu Follitropin, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

Fosamprenavir calcium: ↓ Amprenavir ↓ Ethinyl estradiol May lead to loss of virologic response. a Fosamprenavir calcium/ritonavir: ↓ Ethinyl estradiol Increased risk of transaminase elevations. (Fachinformation zu Fosamprenavir, Arzneimittelwechselwirkungen)

Hormonal Contraceptives: Efficacy of contraceptives may be reduced during treatment and for 1 month following administration of the last dose of either fosaprepitant or oral aprepitant. (Fachinformation zu Fosaprepitant, Warnhinweise und Vorsichtsmaßnahmen)

…omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels Antineoplastic… (Fachinformation zu Fosphenytoin, Arzneimittelwechselwirkungen)

Oral Contraceptive Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg three times a day; N=13). (Fachinformation zu Gabapentin, Arzneimittelwechselwirkungen)

…medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs… (Fachinformation zu Glimepirid, Arzneimittelwechselwirkungen)

…GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline),… (Fachinformation zu Glipizid, Arzneimittelwechselwirkungen)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (Fachinformation zu Goserelin, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

• Large doses of salicylates, cortisone, adrenocorticotropic hormone (ACTH), estrogens or antihistamines may require larger amounts of hyaluronidase for equivalent dispersing effect ( 7.4 ) (Fachinformation zu Hyaluronidase, Arzneimittelwechselwirkungen)

Intervention: Concomitant use of estrogen/estrogen containing products may require an increase in the ALKINDI SPRINKLE dose. (Fachinformation zu Hydrocortison, Arzneimittelwechselwirkungen)

Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

Plasma cholinesterase activity may be decreased by chronic administration of certain monoamine oxidase inhibitors, oral contraceptives, glucocorticoids, antimyasthenics (neostigmine), cyclophosphamide, and possibly thiotepa. (Fachinformation zu Kokain, Arzneimittelwechselwirkungen)

Concomitant Use with Estrogen-Containing Products, Including Oral Contraceptives Some estrogen-containing oral contraceptives have been shown to decrease serum concentrations of lamotrigine [see Clinical Pharmacology ( 12.3 )] . (Fachinformation zu Lamotrigin, Warnhinweise und Vorsichtsmaßnahmen)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (Fachinformation zu Leflunomid, Arzneimittelwechselwirkungen)

ESAs and estrogens may further increase the risk of thrombosis and their use should be based on a benefit-risk decision in patients receiving REVLIMID [see Drug Interactions (7.2) ]. (Fachinformation zu Lenalidomid, Warnhinweise und Vorsichtsmaßnahmen)

Tumor Flare: Increased serum testosterone (~ 50% above baseline) may occur when initiating treatment with LUPRON DEPOT. (Fachinformation zu Leuprorelin, Warnhinweise und Vorsichtsmaßnahmen)

…1: Drugs That May Alter T 4 and Triiodothyronine (T 3 ) Serum Transport Without Effecting Free Thyroxine (FT 4 ) Concentration (Euthyroidism) Drug or Drug Class Effect Clofibrate Estrogen-containing oral contraceptives Estrogens (oral) Heroin/Methadone 5-Fluorouracil Mitotane Tamoxifen These drugs may increase serum thyroxine-binding globulin (TBG) concentration. (Fachinformation zu Levothyroxin, Arzneimittelwechselwirkungen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Table 2: Drugs That May Alter Triiodothyronine (T3) Serum Transport Without Affecting Free Thyroxine (FT4) Concentration (Euthyroidism) Drug or Drug Class Effect Clofibrate Estrogen-containing oral contraceptives Estrogens (oral) Heroin/Methadone 5-Fluorouracil Mitotane Tamoxifen These drugs may increase serum thyroxine-binding globulin (TBG) concentration. (Fachinformation zu Liothyronin, Arzneimittelwechselwirkungen)

Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (Fachinformation zu Lomitapid, Warnhinweise und Vorsichtsmaßnahmen)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (Fachinformation zu Lorlatinib, Warnhinweise und Vorsichtsmaßnahmen)

However, clinical studies have shown that lovastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve, and does not reduce basal plasma testosterone concentration. (Fachinformation zu Lovastatin, Arzneimittelwechselwirkungen)

Estrogens, including oral contraceptives : Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Fachinformation zu Methylprednisolon, Arzneimittelwechselwirkungen)

Mycophenolate mofetil may reduce effectiveness of oral contraceptives. (Fachinformation zu Mycophenolat, Arzneimittelwechselwirkungen)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (Fachinformation zu Nevirapin, Arzneimittelwechselwirkungen)

Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

Hormonal contraceptive ethinyl estradiol ↓ ethinyl estradiol An additional, non-hormonal method of contraception should be considered during the 5 days of PAXLOVID treatment and until one menstrual cycle after stopping PAXLOVID. (Fachinformation zu Nirmatrelvir und Ritonavir, Arzneimittelwechselwirkungen)

Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

Oral Contraceptive: TRILEPTAL may decrease the effectiveness of hormonal contraceptives ( 7.3 ) (Fachinformation zu Oxcarbazepin, Arzneimittelwechselwirkungen)

Contraceptives: 12 mg once daily may decrease the effectiveness of hormonal contraceptives containing levonorgestrel ( 7.1 ) (Fachinformation zu Perampanel, Arzneimittelwechselwirkungen)

Oral Contraceptives Clinical Impact Co-administration of multiple-dose phentermine and topiramate extended-release capsules 15 mg/92 mg once daily with a single dose of oral contraceptive containing 35 µg ethinyl estradiol (estrogen component) and 1 mg norethindrone (progestin component), in obese otherwise healthy volunteers, decreased the exposure of ethinyl… (Fachinformation zu Phentermin und Topiramat, Arzneimittelwechselwirkungen)

…omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels Antacids… (Fachinformation zu Phenytoin, Arzneimittelwechselwirkungen)

…anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs… (Fachinformation zu Pioglitazon und Glimepirid, Arzneimittelwechselwirkungen)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (Fachinformation zu Pitolisant, Arzneimittelwechselwirkungen)

Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (Fachinformation zu Prednisolon, Arzneimittelwechselwirkungen)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Fachinformation zu Prednison, Arzneimittelwechselwirkungen)

Reproductive effects: Include decreased testosterone and increased prolactin levels. (Fachinformation zu Ramelteon, Warnhinweise und Vorsichtsmaßnahmen)

Telaprevir Decrease AUC by 92% Systemic Hormonal Contraceptives Prevention or Management: Advise patients to change to non-hormonal methods of birth control during rifampin therapy Estrogens Decrease exposure Progestins Anticonvulsants Phenytoin Administered with rifampin 450 mg daily Decrease exposure Antiarrhythmics Disopyramide Decrease exposure Mexiletine… (Fachinformation zu Rifampicin, Arzneimittelwechselwirkungen)

Hormonal Contraceptives PRIFTIN may reduce the effectiveness of hormonal contraceptives. (Fachinformation zu Rifapentin, Arzneimittelwechselwirkungen)

The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

Oral Contraceptives or Patch Contraceptives: ethinyl estradiol ↓ ethinyl estradiol Alternate methods of contraception should be considered. (Fachinformation zu Ritonavir, Arzneimittelwechselwirkungen)

Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (Fachinformation zu Roflumilast, Arzneimittelwechselwirkungen)

Estrogens Population pharmacokinetic analysis revealed that higher doses of estrogens (usually associated with hormone replacement therapy) reduced the clearance of ropinirole. (Fachinformation zu Ropinirol, Arzneimittelwechselwirkungen)

Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (Fachinformation zu Somatropin, Arzneimittelwechselwirkungen)

Abiraterone: Spironolactone binds to the androgen receptor and may increase prostate‑specific antigen (PSA) levels in abiraterone-treated prostate cancer patients. (Fachinformation zu Spironolacton und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Therefore, the administration of a bolus dose of BRIDION is considered to be equivalent to missing dose(s) of oral contraceptives containing an estrogen or progestogen. (Fachinformation zu Sugammadex, Arzneimittelwechselwirkungen)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (Fachinformation zu Suxamethonium, Arzneimittelwechselwirkungen)

…contraceptives containing progestins other than levonorgestrel and norethindrone should use additional nonhormonal contraceptives (such as condoms) or use alternative contraceptives (e.g., a combined oral contraceptive containing ethinyl estradiol as the estrogen and levonorgestrel or norethindrone as the progestin, an intrauterine system) during JOURNAVX treatment and… (Fachinformation zu Suzetrigin, Warnhinweise und Vorsichtsmaßnahmen)

Risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (Fachinformation zu Tacrolimus, Arzneimittelwechselwirkungen)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (Fachinformation zu Tamoxifen, Warnhinweise und Vorsichtsmaßnahmen)

Effect of AUBAGIO on Oral Contraceptives AUBAGIO may increase the systemic exposures of ethinylestradiol and levonorgestrel. (Fachinformation zu Teriflunomid, Arzneimittelwechselwirkungen)

Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

Chronic increase in serum prolactin levels (although not evaluated in the tetrabenazine development program) has been associated with low levels of estrogen and increased risk of osteoporosis. (Fachinformation zu Tetrabenazin, Warnhinweise und Vorsichtsmaßnahmen)

Estrogen Estrogen containing oral contraceptives decrease theophylline clearance in a dose-dependent fashion. (Fachinformation zu Theophyllin, Arzneimittelwechselwirkungen)

Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (Fachinformation zu Tocilizumab, Arzneimittelwechselwirkungen)

Patients taking estrogen-containing or progestin-only contraceptives should be asked to report any change in their bleeding patterns. (Fachinformation zu Topiramat, Arzneimittelwechselwirkungen)

Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Fachinformation zu Triamcinolon, Arzneimittelwechselwirkungen)

Tumor Flare: Transient increase in serum testosterone levels can occur within the first few weeks of treatment. (Fachinformation zu Triptorelin, Warnhinweise und Vorsichtsmaßnahmen)

Advise women to follow the instructions on the initiation or resumption of hormonal contraceptives after ella intake [see Dosage and Administration(2.2) ]. (Fachinformation zu Ulipristal, Warnhinweise und Vorsichtsmaßnahmen)

Drugs Affecting Lipid Metabolism Estrogens, oral contraceptives, and clofibrate (and perhaps other lipid-lowering drugs) increase hepatic cholesterol secretion and encourage cholesterol gallstone formation and hence may counteract the effectiveness of URSO 250 and URSO Forte. (Fachinformation zu Ursodesoxycholsäure, Arzneimittelwechselwirkungen)

Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (Fachinformation zu Valproat-Seminatrium (Divalproex), Arzneimittelwechselwirkungen)

Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives: Monitoring of valproate concentrations is recommended (7.1) (Fachinformation zu Valproinsäure, Arzneimittelwechselwirkungen)

Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (Fachinformation zu Acarbose, Arzneimittelwechselwirkungen)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

Alternative or concomitant methods of contraception are recommended for patients taking steroidal contraceptives (e.g., ethinyl estradiol) when treated concomitantly with NUVIGIL and for one month after discontinuation of NUVIGIL treatment. (Fachinformation zu Armodafinil, Arzneimittelwechselwirkungen)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Fachinformation zu Bexaroten, Arzneimittelwechselwirkungen)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (Fachinformation zu Calciumgluconat, Arzneimittelwechselwirkungen)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

Effect of SYMPAZAN ® on Other Drugs Hormonal Contraceptives SYMPAZAN ® is a weak CYP3A4 inducer. (Fachinformation zu Clobazam, Arzneimittelwechselwirkungen)

Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine. (Fachinformation zu Clozapin, Arzneimittelwechselwirkungen)

These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Dapagliflozin und Metformin, Arzneimittelwechselwirkungen)

Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective. (Fachinformation zu Demeclocyclin, Arzneimittelwechselwirkungen)

Oral Contraceptives The effect of oral contraceptives on the pharmacokinetics of Dihydroergotamine Mesylate Injection, USP has not been studied. (Fachinformation zu Dihydroergotamin, Arzneimittelwechselwirkungen)

Concurrent use of tetracyclines, including doxycycline hyclate may render oral contraceptives less effective. (Fachinformation zu Doxycyclin, Arzneimittelwechselwirkungen)

Hormonal contraceptives: Oral Ethinyl estradiol/ Norgsetimate Implant Etonogestrel ↑ active metabolites of norgestimate * ↓ etonogestrel A reliable method of barrier contraception should be used in addition to hormonal contraceptives. (Fachinformation zu Efavirenz, Arzneimittelwechselwirkungen)

Hormonal contraceptives: Oral Ethinyl estradiol/ Norgestimate ↓ active metabolites of norgestimate A reliable method of barrier contraception should be used in addition to hormonal contraceptives. (Fachinformation zu Efavirenz, Lamivudin und Tenofovir, Arzneimittelwechselwirkungen)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Empagliflozin und Metformin, Arzneimittelwechselwirkungen)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Glibenclamid, Arzneimittelwechselwirkungen)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Glibenclamid und Metformin, Arzneimittelwechselwirkungen)

These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Glipizid und Metformin, Vorsichtsmaßnahmen)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

Oral Contraceptives Isotretinoin Capsules did not result in clinically significant changes in the pharmacokinetics of norethindrone and ethinyl estradiol when used concomitantly with a norethindrone and ethinyl estradiol oral contraceptive [see Clinical Pharmacology ( 12.3 )]. (Fachinformation zu Isotretinoin, Arzneimittelwechselwirkungen)

Potential pharmacokinetic interactions of or with levetiracetam were assessed in clinical pharmacokinetic studies (phenytoin, valproate, warfarin, digoxin, oral contraceptive, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients. (Fachinformation zu Levetiracetam, Arzneimittelwechselwirkungen)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Linagliptin und Metformin, Arzneimittelwechselwirkungen)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

Contraceptive: ethinyl estradiol* ↓ ethinyl estradiol Because contraceptive steroid concentrations may be altered when KALETRA is co-administered with oral contraceptives or with the contraceptive patch, alternative methods of nonhormonal contraception are recommended. (Fachinformation zu Lopinavir und Ritonavir, Arzneimittelwechselwirkungen)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Metformin, Arzneimittelwechselwirkungen)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

Drug interaction studies were conducted in adult patients to investigate the effect of coadministered drugs on the pharmacokinetics of mirabegron and the effect of mirabegron on the pharmacokinetics of coadministered drugs (e.g., ketoconazole, rifampin, solifenacin succinate, tamsulosin, and oral contraceptives) [see Clinical Pharmacology ( 12.3 )] . (Fachinformation zu Mirabegron, Arzneimittelwechselwirkungen)

Alternative or concomitant methods of contraception are recommended for patients taking steroidal contraceptives (e.g., ethinyl estradiol) when treated concomitantly with PROVIGIL and for one month after discontinuation of PROVIGIL treatment. (Fachinformation zu Modafinil, Arzneimittelwechselwirkungen)

Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor). (Fachinformation zu Natrium-Zirconium-Cyclosilicat, Arzneimittelwechselwirkungen)

Moderate and weak CYP3A4 inhibitors include alprozalam, ameprenavir, amiodarone, aprepitant, atazanavir, cimetidine, cyclosporine, diltiazem, erythromycin, fluconazole, fluoxetine, isoniazid, oral contraceptives, quinuprestin/dalfopristin, valproic acid, and verapamil. (Fachinformation zu Nimodipin, Arzneimittelwechselwirkungen)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

…performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (Fachinformation zu Pilocarpin, Arzneimittelwechselwirkungen)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Pioglitazon und Metformin, Arzneimittelwechselwirkungen)

No pharmacokinetic interactions were observed between LYRICA and carbamazepine, gabapentin, lamotrigine, oral contraceptive, phenobarbital, phenytoin, topiramate, and valproic acid. (Fachinformation zu Pregabalin, Arzneimittelwechselwirkungen)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (Fachinformation zu Repaglinid, Arzneimittelwechselwirkungen)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (Fachinformation zu Risedronsäure, Arzneimittelwechselwirkungen)

Hormonal contraceptives may be less effective with BANZEL; use additional non-hormonal forms of contraception ( 7.3 ) (Fachinformation zu Rufinamid, Arzneimittelwechselwirkungen)

These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Saxagliptin und Metformin, Arzneimittelwechselwirkungen)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Sitagliptin und Metformin, Arzneimittelwechselwirkungen)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers. (Fachinformation zu Terbinafin, Arzneimittelwechselwirkungen)

Concurrent use of tetracycline may render oral contraceptives less effective. (Fachinformation zu Tetracyclin, Arzneimittelwechselwirkungen)

Oral Contraceptives Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective. (Fachinformation zu Tigecyclin, Arzneimittelwechselwirkungen)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

Oral Contraceptives In vivo studies have revealed no effect of ziprasidone on the pharmacokinetics of estrogen or progesterone components. (Fachinformation zu Ziprasidon, Arzneimittelwechselwirkungen)

No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed. (Fachinformation zu Acebutolol, Arzneimittelwechselwirkungen)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Fachinformation zu Alosetron, Arzneimittelwechselwirkungen)

Combination oral contraceptives Darifenacin (10 mg three times daily) had no effect on the pharmacokinetics of the combination oral contraceptives containing levonorgestrel and ethinyl estradiol [see Clinical Pharmacology (12.3)] . (Fachinformation zu Darifenacin, Arzneimittelwechselwirkungen)

Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides), and theophylline did not affect the pharmacokinetics of dofetilide. (Fachinformation zu Dofetilid, Arzneimittelwechselwirkungen)

No clinically significant drug interactions have been either observed or are expected when DESCOVY is combined with the following drugs: buprenorphine, itraconazole, ketoconazole, lorazepam, methadone, midazolam, naloxone, norbuprenorphine, norgestimate/ethinyl estradiol, and sertraline. (Fachinformation zu Emtricitabin und Tenofovir, Arzneimittelwechselwirkungen)

No clinically significant drug interactions have been observed between TDF and the following medications: entecavir, methadone, oral contraceptives, ribavirin, sofosbuvir, or tacrolimus in studies conducted in healthy subjects. (Fachinformation zu Emtricitabin, Rilpivirin und Tenofovir, Arzneimittelwechselwirkungen)

Oral Contraceptives In the presence of fesoterodine, there are no clinically significant changes in the plasma concentrations of combined oral contraceptives containing ethinyl estradiol and levonorgestrel [see Clinical Pharmacology (12.3) ] . (Fachinformation zu Fesoterodin, Arzneimittelwechselwirkungen)

…sofosbuvir is used with the following drugs [see Clinical Pharmacology (12.3) ]: abacavir, atazanavir/ritonavir, cyclosporine, darunavir/ritonavir, dolutegravir, efavirenz, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, emtricitabine, lamivudine, methadone, midazolam, oral contraceptives, pravastatin, raltegravir, rilpivirine, tacrolimus, or verapamil. (Fachinformation zu Ledipasvir und Sofosbuvir, Arzneimittelwechselwirkungen)

No dose adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology… (Fachinformation zu Montelukast, Arzneimittelwechselwirkungen)

Drugs without Clinically Significant Interactions with ISENTRESS In drug interaction studies, raltegravir did not have a clinically meaningful effect on the pharmacokinetics of the following: hormonal contraceptives, methadone, lamivudine, tenofovir, etravirine, darunavir/ritonavir, or boceprevir. (Fachinformation zu Raltegravir, Arzneimittelwechselwirkungen)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (Fachinformation zu Rizatriptan, Arzneimittelwechselwirkungen)

…clinically significant drug interactions have been observed with the following drugs [see Clinical Pharmacology (12.3) ]: VOSEVI: cobicistat, darunavir, elvitegravir, emtricitabine, ethinyl estradiol/norgestimate, gemfibrozil, rilpivirine, ritonavir, tenofovir alafenamide, voriconazole Sofosbuvir/velpatasvir: dolutegravir, ketoconazole, raltegravir Sofosbuvir:… (Fachinformation zu Sofosbuvir und Velpatasvir, Arzneimittelwechselwirkungen)

Oral Contraceptives : Multiple dose administration of tiagabine (8 mg/day monotherapy) did not alter the pharmacokinetics of oral contraceptives in healthy women of child-bearing age. (Fachinformation zu Tiagabin, Arzneimittelwechselwirkungen)

In a single-blind, parallel-group, 3-week study in 39 healthy female subjects taking oral contraceptives, 40 mg twice daily of zafirlukast had no significant effect on ethinyl estradiol plasma concentrations or contraceptive efficacy. (Fachinformation zu Zafirlukast, Vorsichtsmaßnahmen)

Other Concomitant Drug Therapy Drug-drug interaction studies conducted in healthy subjects between zileuton immediate-release tablets and prednisone and ethinyl estradiol (oral contraceptive), drugs known to be metabolized by the CYP3A4 isoenzyme, have shown no significant interaction. (Fachinformation zu Zileuton, Arzneimittelwechselwirkungen)